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PaBACKGROUND Little evidence exists of the burden and predictors of cardiac death after transcatheter aortic valve
replacement (TAVR).
OBJECTIVES The purpose of this study was to assess the incidence and predictors of cardiac death from advanced
heart failure (HF) and sudden cardiac death (SCD) in a large patient cohort undergoing TAVR.
METHODS The study included a total of 3,726 patients who underwent TAVR using balloon (57%) or self-expandable
(43%) valves. Causes of death were deﬁned according to the Valve Academic Research Consortium–2.
RESULTS At a mean follow-up of 22  18 months, 155 patients had died due to advanced HF (15.2% of total deaths,
46.1% of deaths from cardiac causes) and 57 had died due to SCD (5.6% of deaths, 16.9% of cardiac deaths). Baseline
comorbidities (chronic obstructive pulmonary disease, atrial ﬁbrillation, left ventricular ejection fraction #40%, lower
mean transaortic gradient, pulmonary artery systolic pressure >60 mm Hg; p < 0.05 for all) and 2 procedural factors
(transapical approach, hazard ratio [HR]: 2.38, 95% conﬁdence interval [CI]: 1.60 to 3.54; p < 0.001; presence of
moderate or severe aortic regurgitation after TAVR, HR: 2.79, 95% CI: 1.82 to 4.27; p < 0.001) independently predicted
death from advanced HF. Left ventricular ejection fraction #40% (HR: 1.93, 95% CI: 1.05 to 3.55; p ¼ 0.033) and new-
onset persistent left bundle-branch block following TAVR (HR: 2.26, 95% CI: 1.23 to 4.14; p ¼ 0.009) were indepen-
dently associated with an increased risk of SCD. Patients with new-onset persistent left bundle-branch block and a QRS
duration >160 ms had a greater SCD risk (HR: 4.78, 95% CI: 1.56 to 14.63; p ¼ 0.006).
CONCLUSIONS Advanced HF and SCD accounted for two-thirds of cardiac deaths in patients after TAVR.
Potentially modiﬁable or treatable factors leading to increased risk of mortality for HF and SCD were identiﬁed. Future
studies should determine whether targeting these factors decreases the risk of cardiac death. (J Am Coll Cardiol
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AR = aortic regurgitation
AVB = atrioventricular block
HF = heart failure
LBBB = left bundle-branch
block
LVEF = left ventricular ejection
fraction
NOP = new-onset persistent
PASP = pulmonary artery
systolic pressure
PPM = permanent pacemaker
SCD = sudden cardiac death
TAVR = transcatheter aortic
valve replacement
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438T ranscatheter aortic valve replace-ment (TAVR) improves survival inpatients with symptomatic aortic
stenosis who are deemed to be at high or pro-
hibitive surgical risk (1). However, in initial
studies, approximately 1 of 4 patients died
during the ﬁrst year following TAVR despite
relief of the valvular obstruction, highlighting
the need to improve patient selection (2).
Such efforts have reduced overall mortality
after TAVR (3), mainly due to decreased inci-
dence of noncardiac death, without signiﬁ-
cant changes in the cardiac death rate.SEE PAGE 449The persistent risk of death from advanced
heart failure (HF) andsuddencardiacdeath (SCD)in patients undergoing surgical aortic valve replacement
(SAVR), the most common modes of death following
SAVR, has long been of concern (4–7). Some studies
suggested that the risks of cardiac death and SCD are
increased by potentially treatable factors, such as new
conduction disturbances (4,6,8,9). Although there is little
evidence of the burden of death from advanced HF and
SCD in patients undergoing TAVR, both accounted
for approximately three-fourths of cardiac deaths in some
previous studies (10–12). However, their predictors remain
largely unknown. More importantly, whether potentially
treatable or modiﬁable factors might increase the risk of
death from HF and SCD after TAVR has not yet been
elucidated. The objective of this study was, therefore, to
assess the incidence and predictors of death from
advanced HF and SCD in patients undergoing TAVR.
METHODS
STUDY POPULATION. The study included 3,726 total
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for TAVR and approach were assessed by each
center’s heart team, and TAVR procedures were
performed as described (1), with data prospec-
tively collected in a dedicated database in each
center. Clinical outcomes were deﬁned according
to VARC (Valve Academic Research Consortium)-2
criteria (2).
ELECTROCARDIOGRAPHY AND ECHOCARDIOGRAPHY
DATA. Twelve-lead electrocardiography (ECG) trac-
ings were recorded at least at baseline, immediately
after the procedure, and at hospital discharge.
ECGs at baseline and at hospital discharge were
obtained in 95% of patients. American Heart Asso-
ciation/American College of Cardiology Foundation/
Heart Rhythm Society recommendations for stan-
dardization and interpretation of the electrocar-
diogram (13) were the basis for diagnosis of
intraventricular conduction abnormalities. New-
onset persistent (NOP) left bundle-branch block
(LBBB) was deﬁned as a new LBBB in a patient
without a prior permanent pacemaker (PPM), which
persisted at hospital discharge or until death. Pri-
mary analyses excluded patients who developed
new-onset LBBB and required PPM implantation
during the hospitalization period. In a supplemen-
tary analysis, patients were classiﬁed into 3 groups:
NOP-LBBB (no pacemaker); new-onset persistent
LBBB and pacemaker during hospitalization (NOP-
LBBB-PPM); and no NOP-LBBB. A PPM was im-
planted if third-degree or advanced second-degree
atrioventricular block (AVB) occurred at any ana-
tomical level and was not expected to resolve, or in
the presence of sinus node dysfunction and docu-
mented symptomatic bradycardia, in agreement with
current recommendations (14). In the presence of
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TABLE 2 Causes of Cardiovascular Death After Transcatheter
Aortic Valve Implantation (N ¼ 663)
Cardiac death 336 (50.7)
Advanced heart failure 155 (23.4)
Sudden cardiac death 57 (8.6)
Myocardial infarction 32 (4.8)
Endocarditis 17 (2.6)
Other procedure-related cardiac complications 75 (11.3)
Noncoronary vascular related death 69 (10.4)
Other procedure-related complications 163 (24.6)
Unknown 95 (14.3)
Values are n (%).
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439(>200 ms) or very wide QRS (>150 ms) not expected
to normalize, indication for PPM was at the physi-
cian’s discretion.
Experienced echocardiographers at each center
analyzed echocardiograms. The degree of aortic
regurgitation (AR) was classiﬁed according to the
VARC-2 criteria (2). Left ventricular ejection fraction
(LVEF) was calculated using Simpson’s rule.
FOLLOW-UP. Follow-up was by telephone and/or
outpatient clinic visits at 1 month after TAVR, at
1 year, and yearly thereafter. Complete follow-up wasTABLE 1 Baseline Clinical Characteristics, Procedural Findings,
and 30-Day Outcomes of the Study Population (N ¼ 3,726)
Clinical characteristics and electrocardiographic
ﬁndings
Age, yrs 81  8
Male 1,866/3,718 (50.2)
Body mass index, kg/m2 27  5
NYHA functional class $III 2,740/3,668 (74.7)
Hypertension 2,854/3,704 (77.1)
Diabetes mellitus 1,118/3,706 (30.2)
COPD 955/3,685 (25.9)
eGFR <60 ml/min 1,864/3,638 (51.2)
Coronary artery disease 1,987/3,705 (53.6)
Complete or no need of revascularization 2,216/3,349 (66.2)
Paroxysmal/chronic AF 1,093/3,628 (30.1)
Pre-existing LBBB 330/3,540 (9.3)
Prior pacemaker 415/3,710 (11.2)
Logistic EuroSCORE, % 19.4  13.0
Echocardiographic ﬁndings
LVEF #40% 682/3,657 (18.6)
Mean transaortic gradient, mm Hg 47  17
PASP >60 mm Hg 376/2,748 (13.7)
Procedural ﬁndings
Approach
Transfemoral 2,958/3,713 (79.7)
Transapical 607/3,713 (16.3)
Transaortic 69/3,713 (1.9)
Subclavian 79/3,713 (2.1)
Prosthesis type
Self-expandable 1,559/3,717 (43.0)
Balloon-expandable 2,118/3,717 (57.0)
Moderate or severe AR 374/3,407 (11.0)
30-day outcomes
Death 271 (7.3)
Stroke 114/3,666 (3.1)
Myocardial infarction 52/3,287 (1.6)
Major or life threatening bleeding 479/3,480 (13.8)
NOP-LBBB 471/3,539 (13.3)
PPM implantation 536/3,666 (14.6)
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; AR ¼ aortic regurgitation; COPD ¼ chronic obstructive
pulmonary disease; eGFR ¼ estimated glomerular ﬁltration ratio; LBBB ¼ left
bundle-branch block; LVEF ¼ left ventricular ejection fraction; NOP-LBBB ¼ new-
onset persistent left bundle-branch block; NYHA ¼ New York Heart Association;
PASP ¼ pulmonary artery systolic pressure; PPM ¼ permanent pacemaker.achieved in 95.9% of patients (4.1% of the study
population was lost to follow-up).
DEFINITION OF CAUSES OF DEATH. Causes of death
were obtained by scrutinizing medical charts and
by telephone calls or interviews with families and
physicians. Civil registries were consulted when
necessary. Cardiovascular death was deﬁned accord-
ing to VARC-2 criteria. Any death attributable to
a proximate cardiac cause or death of an unknown
cause was classiﬁed as cardiac death. SCD was
deﬁned, in accordance with the World Health Orga-
nization deﬁnition, as a death occurring within 1 h of
symptom onset if witnessed or within the previous
24 h if unwitnessed. Patients with known terminal
disease or an identiﬁable noncardiac etiology ofFIGURE 1 Rates of Overall and Cardiac Mortality
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FIGURE 2 Rates of Death From Advanced Heart Failure and Sudden Cardiac Death
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440sudden death were not considered to have experi-
enced SCD (15).
STATISTICAL ANALYSIS. Qualitative variables are
expressed as n (percentage) and quantitative vari-
ables as mean  SD. Survival rates were summarized
using Kaplan-Meier estimates, and log-rank tests
were used to perform comparisons between groups.
Predictors of death from HF and SCD were analyzed
using univariate and multivariate proportional
hazard models (cumulative outcomes). Hazard pro-
portional assumption was evaluated by means of log-
minus-log survival plots. A Fine-Gray Cox model wasconstructed to account for death from other causes as
a competing risk event for death from HF and SCD.
Variables with p values <0.10 in the univariate ana-
lyses were included in the multivariate analysis. All
univariate analyses were performed on complete
cases.
Overall, 3.4% of data were missing, and 23.4% of
patients had missing data for at least 1 variable.
Missing data were assumed to be random and were
dealt with through the multiple imputation proce-
dure using the Markov Chain Monte Carlo method.
Ten imputed datasets were created, and results were
pooled according to Rubin’s protocol (16). Multivar-
iate models using complete-case analyses were also
performed. The optimal cutoff value for QRS duration
to predict SCD in patients with NOP-LBBB was
deﬁned using receiver-operating characteristic curves
and the maximum Youden’s index (sensitivity þ
speciﬁcity  1) (17). Results with p values <0.05 were
considered signiﬁcant. Statistical analyses were con-
ducted using SAS version 9.2 (SAS Institute, Inc.,
Cary, North Carolina) and the Statistical Package for
Social Sciences version 20 (SPSS Inc., IBM, Armonk,
New York).
RESULTS
Table 1 shows the main clinical characteristics, echo-
cardiographic and procedural ﬁndings, and 30-day
outcomes of the study population. The mean age of
the study population was 81  8 years, and 50.2% of
patients were males. The mean logistic EuroSCORE
was 19.4  13.0%. Balloon- and self-expandable
valves were used in 57% and 43% of patients,
respectively, and TAVR was performed through the
transfemoral route in 79.7% of patients and the
transapical route in 16.3%. After TAVR, moderate to
severe AR was observed in 374 patients (11.0%) and
NOP-LBBB occurred in 471 patients (13.3%). At 30
days after TAVR, mortality and stroke rates were 7.3%
and 3.1%, respectively.
INCIDENCE OF DEATH FROM ADVANCED HF AND SCD.
At a mean follow-up of 22  18 months, 1,022 patients
(27.4%) had died, 663 (17.8%) from cardiovascular
causes. Cardiac death was conﬁrmed in 336 patients
(33.0% of deaths). Table 2 shows causes of cardio-
vascular death in the study population. Cumulative
rates of overall mortality and cardiac mortality at
2-year follow-up were 26.6% (95% conﬁdence interval
[CI]: 25.3% to 28.8%) and 9.6% (95% CI: 8.4% to
10.8%), respectively (Figure 1). Death from advanced
HF occurred in 155 patients (4.2%), accounting for
15.2% of total deaths and 46.1% of cardiac deaths.
Cumulative rates of death from advanced HF at 1- and
TABLE 3 Univariate and Multivariate Predictors of Terminal Heart Failure
Following TAVR
Univariate HR
(95% CI) p Value
Multivariate HR*
(95% CI) p Value
Clinical characteristics and
electrocardiographic ﬁndings
Age, yrs 1.02 (0.99–1.04) 0.162
Male 1.22 (0.90–1.67) 0.225
Body mass index, kg/m2 0.98 (0.94–1.01) 0.134
NYHA functional class $III 1.75 (1.12–2.73) 0.014 1.19 (0.72–1.96) 0.502
Hypertension 1.33 (0.88–2.02) 0.176
Diabetes mellitus 1.01 (0.71–1.44) 0.939
COPD 1.54 (1.10–2.15) 0.011 1.59 (1.11–2.29) 0.012
eGFR <60 ml/min 1.36 (0.98–1.91) 0.058 0.64 (0.29–1.37) 0.248
Coronary artery disease 1.36 (0.98–1.87) 0.066 1.04 (0.61–1.77) 0.891
Complete or no need of
revascularization
0.66 (0.47–0.92) 0.015 1.01 (0.59–1.71) 0.985
Paroxysmal/chronic AF 2.58 (1.87–3.56) <0.001 2.33 (1.62–3.35) <0.001
Pre-existing LBBB 0.73 (0.38–1.38) 0.329
Prior pacemaker 1.60 (1.04–2.46) 0.031 0.87 (0.54–1.40) 0.564
Echocardiographic ﬁndings
LVEF #40% 1.87 (1.31–2.66) 0.001 1.68 (1.10–2.56) 0.017
Mean transaortic gradient
(mm Hg)†
1.22 (1.11–1.35) <0.001 1.11 (1.02–1.22) 0.040
PASP >60 mm Hg 1.85 (1.22–2.80) 0.004 1.99 (1.21–3.28) 0.007
Procedural ﬁndings
Transapical approach 3.16 (2.29–4.38) <0.001 2.38 (1.60–3.54) <0.001
Balloon-expandable
prosthesis type
2.72 (1.88–3.94) <0.001 1.06 (0.55–2.06) 0.854
Moderate or severe AR 1.83 (1.19–2.84) 0.006 2.79 (1.82–4.27) <0.001
30-day outcomes
Stroke 1.97 (0.97–4.01) 0.063 1.89 (0.91–3.95) 0.090
Myocardial infarction 2.48 (0.92–6.71) 0.074 2.37 (0.86–6.54) 0.097
Major or life threatening
bleeding
1.39 (0.91–2.14) 0.132
NOP-LBBB 0.95 (0.60–1.51) 0.833
PPM implantation 0.62 (0.37–1.04) 0.070 0.78 (0.42–1.44) 0.422
*For the multivariate analysis, patients with missing data were included through the use of multiple imputation.
†Per 10-mm Hg decrease.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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4412-year follow-up were 2.9% (95% CI: 2.3% to 3.5%)
and 4.4% (95% CI: 3.7% to 5.2%), respectively
(Figure 2A). A total of 57 patients died from SCD (5.6%,
16.9% of cardiac deaths), and the cumulative rates of
SCD at 1- and 2-year follow-up were 1.0% (95% CI:
0.6% to 1.4%) and 1.8% (95% CI: 1.2% to 2.4%),
respectively (Figure 2B).
PREDICTORS OF DEATH FROM ADVANCED HF.
Table 3 shows predictors of death from advanced
HF. In the multivariate analysis, baseline characteris-
tics such as chronic obstructive pulmonary disease
(hazard ratio [HR]: 1.59, 95% CI: 1.11 to 2.29; p ¼ 0.012),
pre-existing paroxysmal or chronic atrial ﬁbrillation
(HR: 2.33, 95% CI: 1.62 to 3.35; p < 0.001), LVEF #40%
(HR: 1.68, 95% CI:1.10 to 2.56; p ¼ 0.017), a lower mean
transaortic gradient (HR: 1.11, 95% CI: 1.02 to 1.22; p ¼
0.040 per 10-mm Hg decrease), pulmonary artery
systolic pressure [PASP] >60 mm Hg (HR: 1.99, 95%
CI: 1.21 to 3.28; p ¼ 0.007), and 2 procedural factors
such as the use of the transapical route (HR: 2.38, 95%
CI: 1.60 to 3.54; p < 0.001) and the presence of mod-
erate or severe AR after TAVR (HR: 2.79, 95% CI: 1.82
to 4.27; p < 0.001) were associated with increased
risk of death from advanced HF. The same predictors
were found using complete-case analysis. When death
from other causes was considered as a competing
risk event, pre-existing paroxysmal or chronic atrial
ﬁbrillation (HR: 1.88, 95% CI: 1.34 to 2.64; p < 0.001),
LVEF #40% (HR: 1.49, 95% CI: 1.00 to 2.26; p ¼ 0.050),
PASP >60 mm Hg (HR: 1.90, 95% CI: 1.22 to 2.96;
p ¼ 0.005), use of the transapical route (HR: 2.24,
95% CI: 1.54 to 3.26; p < 0.001), and the presence of
moderate or severe AR after TAVR (HR: 2.10, 95%
CI: 1.42 to 3.14; p < 0.001) were also independent
predictors of death from HF.
Figure 3 shows rates of death from HF at 2-year
follow-up according to use of the transapical
approach and the presence of moderate or severe AR
after TAVR. Online Table 1 displays differences
between approach groups in baseline clinical charac-
teristics, echocardiographic and procedural ﬁndings,
and 30-day outcomes. After adjusting for these
differences, the transapical approach remained an
independent predictor of death from advanced HF
(HR: 1.86, 95% CI: 1.20 to 2.86; p ¼ 0.001).
Among the 374 patients with moderate or severe
AR after TAVR, 135 patients (36.1%) had died at last
follow-up, 25 (6.7%) due to advanced HF. A lower
mean transaortic gradient (HR: 1.35, 95% CI: 1.04 to
1.85; p ¼ 0.040 per 10-mm Hg decrease) and a PASP
>60 mm Hg (HR: 3.06, 95% CI: 1.14 to 8.22; p ¼ 0.027)
were independent echocardiographic predictors of
death from HF in these patients, whereas thepresence of moderate or severe AR before TAVR (HR:
0.24, 95% CI: 0.07 to 0.83; p ¼ 0.025) was an inde-
pendent protective factor (Table 4).
In the subgroup of patients with LVEF #40%
(n ¼ 682), moderate or severe prosthesis-patient
mismatch was not associated with an increased risk
of death from HF (HR: 0.94, 95% CI: 0.42 to 2.09;
p ¼ 0.937).
PREDICTORS OF SCD. Table 5 shows the predictors of
SCD. An LVEF #40% before TAVR (HR: 1.93, 95% CI:
1.05 to 3.55; p ¼ 0.033) and the occurrence of NOP-
LBBB (HR: 2.26, 95% CI: 1.23 to 4.14; p ¼ 0.009)
were independently associated with an increased
risk of SCD. The same predictors were found using
complete-case analysis. When considering death from
FIGURE 3 Rates of Mortality From Advanced Heart Failure According to the
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(B). AR ¼ aortic regurgitation; TA ¼ transapical.
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442other causes as a competing risk event, LVEF #40%
(HR: 2.13, 95% CI: 1.17 to 3.87; p ¼ 0.011) and the
occurrence of NOP-LBBB (HR: 2.20, 95% CI: 1.19 to
4.06; p ¼ 0.010) remained independent predictors of
SCD. Figure 4 shows Kaplan-Meier curves for SCD
according to the presence of LVEF #40% and/or NOP-
LBBB. When both were present concomitantly, therisk of sudden death at 1-year follow-up increased to
12.3% (95% CI: 7.1% to 22.5%).
A total of 15 patients with NOP-LBBB (3.2% of
patients with NOP-LBBB) died of SCD at last
follow-up. Table 6 shows electrocardiographic pre-
dictors of SCD in patients with NOP-LBBB. The
receiver-operating characteristic curve showed that
the best QRS duration cut-off for predicting SCD in
patients with NOP-LBBB was >160 ms, with a sensi-
tivity of 38.5% and speciﬁcity of 87.8% (area under
the curve: 0.64, standard error: 0.09). A QRS duration
>160 ms at hospital discharge was associated with an
increased risk of SCD in patients with NOP-LBBB (HR:
4.78, 95% CI: 1.56 to 14.63; p ¼ 0.006). Figure 5 shows
cumulative SCD rates at 2-year follow-up in patients
with NOP-LBBB according to QRS duration (>160
or #160 ms). In patients with QRS duration >160 ms,
the rate of SCD was 9.9% at 1-year follow-up.
In a further analysis, patients were classiﬁed into 3
groups according to the occurrence of new-onset
LBBB and PPM during the hospitalization period:
NOP-LBBB (n ¼ 471 [12.6%]); NOP-LBBB-PPM (n ¼ 92
[2.5%]); and no NOP-LBBB (n ¼ 2,976 [79.9%]). Rea-
sons for PPM in patients with NOP-LBBB were
paroxysmal or transient advanced-degree AVB in 58
patients (63.0%) and prophylactic in 34 patients
(37.0%). Whereas those patients with NOP-LBBB-PPM
had no increased risk of SCD compared with those
with no NOP-LBBB (HR: 0.71, 95% CI: 0.09 to 5.48;
p ¼ 0.740) (Online Table 2), those with NOP-LBBB
(with no PPM) had an increased risk of SCD
compared with those with no NOP-LBBB (HR: 2.21,
95% CI: 1.20 to 4.09; p ¼ 0.011). No signiﬁcant
differences in SCD were observed between the NOP-
LBBB and NOP-LBBB-PPM groups (HR: 3.13, 95% CI:
0.38 to 25.63; p ¼ 0.287). Online Figure 1 displays
Kaplan-Meier curves for SCD according to the occur-
rence of NOP-LBBB (with no PPM), NOP-LBBB-PPM,
or no NOP-LBBB.
DISCUSSION
Advanced HF and SCD were reportedly the most
common causes of death after SAVR, accounting
for >50% of total deaths in most surgical series (4–7).
The percentage of both modes of death versus total
deaths was much lower (w20%) in our study, in
accordance with prior observations in patients un-
dergoing TAVR (11,12). This may be attributable to the
high prevalence of severe noncardiac comorbidities in
this population, leading to a high incidence of death
from noncardiac causes.
DEATH FROM ADVANCED HF FOLLOWING TAVR.
The interplay between chronic obstructive pulmonary
TABLE 4 Echocardiographic Predictors of Death From Heart Failure in Patients With
Moderate or Severe Aortic Regurgitation Following TAVR (n ¼ 374)
Univariate HR
(95% CI) p Value
Multivariate HR
(95% CI) p Value
Baseline
LVEF, % 0.99 (0.97–1.02) 0.591
Mean transaortic gradient, mm Hg 1.35 (1.00–1.66)* 0.048 1.35 (1.04–1.85)* 0.040
PASP >60 mm Hg 2.38 (0.91–6.93) 0.079 3.06 (1.14–8.22) 0.027
Moderate or severe MR 1.55 (0.51–4.68) 0.439
Moderate or severe AR 0.39 (0.14–1.03) 0.058 0.24 (0.07–0.83) 0.025
Discharge
LVEF (%) 0.99 (0.96–1.01) 0.341
Mean gradient 1.00 (0.91–1.10) 0.980
*Per 10-mm Hg decrease.
MR ¼ mitral regurgitation; other abbreviations as in Tables 1 and 3.
TABLE 5 Univariate and Multivariate Predictors of Sudden Cardiac Death Following TAVR
Univariate HR
(95% CI) p Value
Multivariate HR*
(95% CI) p Value
Clinical characteristics and
electrocardiographic ﬁndings
Age, yrs 1.00 (0.97–1.04) 0.862
Male 1.30 (0.77–2.18) 0.329
Body mass index, kg/m2 1.00 (0.95–1.05) 0.918
NYHA functional class $III 1.67 (0.82–3.40) 0.162
Hypertension 1.32 (0.67–2.62) 0.421
Diabetes mellitus 1.56 (0.91–2.67) 0.104
COPD 1.34 (0.77–2.35) 0.305
eGFR <60 ml/min 1.12 (0.65–1.94) 0.684
Coronary artery disease 1.05 (0.62–1.77) 0.865
Complete or no need of
revascularization
0.70 (0.40–1.22) 0.206
Paroxysmal/chronic AF 1.28 (0.73–2.26) 0.386
Pre-existing LBBB 0.56 (0.17–1.78) 0.321
Prior pacemaker 0.47 (0.15–1.51) 0.205
Echocardiographic ﬁndings
LVEF #40% 2.07 (1.17–3.65) 0.013 1.93 (1.05–3.55) 0.033
Mean transaortic gradient
(mm Hg)†
1.22 (1.35–1.00) 0.082 1.11 (0.90–1.34) 0.134
PASP >60 mm Hg 1.09 (0.49–2.43) 0.830
Procedural ﬁndings
Transapical approach 0.46 (0.18–1.16) 0.101
Balloon-expandable
prosthesis type
0.85 (0.51–1.44) 0.550
Moderate or severe AR 1.97 (1.02–3.81) 0.044 1.40 (0.64–3.05) 0.395
30-day outcomes
Stroke 2.94 (1.06–8.14) 0.038 1.85 (0.43–7.89) 0.405
Myocardial infarction — —
Major or life threatening
bleeding
1.24 (0.58–2.62) 0.581
NOP-LBBB 2.00 (1.11–3.61) 0.021 2.26 (1.23–4.14) 0.009
PPM implantation 0.94 (0.44–2.00) 0.871
*For the multivariate analysis, patients with missing data were included through the use of multiple imputation.
†Per 10-mm Hg decrease.
Abbreviations as in Tables 1 and 3.
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443disease, atrial ﬁbrillation, left ventricular dysfunc-
tion, severe pulmonary hypertension, and overt HF
is well known (18). It is not surprising that these
baseline comorbidities predicted the occurrence of
death from advanced HF after TAVR in our study, as all
were previously identiﬁed predictors of poorer out-
comes in patients undergoing TAVR (1,12) and were
associated with increased risk of mortality due to HF
after cardiac surgery (5–7). A lower mean transaortic
gradient, another baseline factor associated with
death from advanced HF following TAVR in our study,
was similarly associated with a higher rate of HF
recurrence, a poorer New York Heart Association
functional class, and a higher rate of death from
HF in patients with aortic stenosis undergoing
SAVR, regardless of the presence of left ventricular
dysfunction (19).
Interestingly, our study identiﬁed 2 potentially
modiﬁable factors as independent predictors of death
from HF: use of the transapical approach and the
presence of moderate or severe AR after TAVR
(Central Illustration). There are some studies sug-
gesting that the use of the transapical (vs. trans-
femoral) approach may increase the risk of mortality
after TAVR (10,20,21), although the causes remain
largely unknown. The present study showed, for the
ﬁrst time to our knowledge, that an approximately
2-fold increased risk of death from HF was asso-
ciated with transapical access. This suggests that the
increased mortality associated with the transapical
approach is driven, at least in part, by a higher rate of
progression to advanced HF. Accordingly, several
studies reported poorer evolution of LVEF in patients
undergoing transapical (vs. transfemoral) procedures
(22,23), attributable to the higher degree of myocar-
dial injury and impairment in left ventricular apical
function (24,25). This may also explain the early
rise in N-terminal prohormone of B-type natriuretic
peptide levels following transapical, but not trans-
femoral, TAVR (26). Our results suggest that alterna-
tives to the transapical route, such as subclavian,
transaortic, or carotid approaches, may be considered
in patients at high risk of advanced HF for whom the
transfemoral approach is not suitable.
Although the presence of residual moderate or
severe AR is a well-established predictor of both
overall and cardiovascular mortality after TAVR
(1,27), the speciﬁc mechanisms leading to increased
mortality have not yet been elucidated. An increased
risk of death from HF was observed in patients with
residual moderate or severe AR in this study, sug-
gesting that progression to advanced HF may
partially explain the excess rate of death. Reports
indicate that this increased risk of mortality
FIGURE 4 Rates of Sudden Cardiac Death According to the Presence of an LVEF #40%
and/or the Occurrence of NOP-LBBB
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A
B
C
Kaplan-Meier curves at 2-year follow-up for sudden cardiac death according to the pres-
ence of a left ventricular ejection fraction (LVEF) #40% (A), new-onset persistent left
bundle-branch block (NOP-LBBB) (B), or both (C).
TABLE 6 Electrocardiographic Predictors of Sudden Cardiac
Death in Patients With New-Onset Persistent Left Bundle-Branch
Block Following TAVR (n ¼ 471)
Univariate HR
(95% CI) p Value
Baseline
QRS duration 1.01 (0.98–1.04) 0.551
PR >200 ms — —
Discharge
QRS duration 1.02 (0.99–1.05) 0.162
QRS >160 ms 4.78 (1.56–14.63) 0.006
PR >200 ms 0.26 (0.03–2.20) 0.218
Abbreviations as in Tables 1 and 3.
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444particularly occurs in patients with a signiﬁcant
increment in the degree of AR following TAVR
compared with baseline, probably due to a sudden
increase in end-diastolic ventricular pressure that
prevents the development of the compensatory
mechanisms present in patients with chronic AR (28).
Accordingly, we observed that the presence of sig-
niﬁcant AR before TAVR had a protective effect on the
risk of death from HF in patients with residual mod-
erate or severe AR. However, both the presence of
severe pulmonary hypertension and a lower trans-
aortic gradient before TAVR were associated with an
increased risk of mortality from HF in such patients.
Development of pulmonary hypertension in patients
with aortic stenosis has been mainly attributed to
diastolic dysfunction (29,30), which markedly re-
duces tolerance to acute AR. Higher pulmonary
pressure levels have been associated with increased
mortality in patients with signiﬁcant AR after TAVR
(31). The presence of lower transaortic gradients may
reﬂect more advanced myocardial disease, even
in the absence of left ventricular dysfunction
(32). Whether therapies directed at reducing the
degree of AR after TAVR (e.g., balloon post-dilation,
valve-in-valve procedures, percutaneous closure of
paravalvular leaks, high pacing rates, surgery) are
associated with a reduction in the rates of mortality
from advanced HF after TAVR should be further
evaluated.
SCD FOLLOWING TAVR. The effect of NOP-LBBB on
mortality after aortic valve replacement has been
highly controversial in both surgical and trans-
catheter ﬁelds (4,9,33–36). Some studies reported an
increased risk of SCD, complete AVB, or syncope in
patients with NOP-LBBB following SAVR (9). In the
TAVR ﬁeld, although NOP-LBBB has been associated
with an increased risk of complete AVB or PPM
implantation during the follow-up period (35,36), no
FIGURE 5 Rate of Sudden Cardiac Death in Patients With New-Onset
Left Bundle-Branch Block
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Kaplan-Meier curves at 2-year follow-up for sudden cardiac death in patients with new-
onset left bundle-branch block, deﬁned by the presence of a QRS duration >160 ms.
J A C C V O L . 6 5 , N O . 5 , 2 0 1 5 Urena et al.
F E B R U A R Y 1 0 , 2 0 1 5 : 4 3 7 – 4 8 Late Cardiac Death After TAVR
445increased rates of SCD were observed in previous
studies assessing the effect of NOP-LBBB (33,34).
However, differences in the deﬁnitions of both SCD
and LBBB (e.g., persistent at hospital discharge vs.
all), and underpowered sample sizes (all previous
studies included <1,200 patients) may partially
explain such differences. Although the speciﬁc causes
of SCD in patients with NOP-LBBB (ventricular
arrhythmia vs. advanced AVB) have not yet been
elucidated, autopsy data has shown necrosis of the
bundle of His and left bundle-branch due to me-
chanical compression by the transcatheter prosthesis
(37), supporting progression to advanced AVB as a
possible mechanism of SCD in such patients. Most
patients with NOP-LBBB and wide QRS died within
the ﬁrst 6 months after TAVR, and no increased risk of
SCD was observed in patients with NOP-LBBB and
PPM implanted before hospital discharge, suggesting
advanced AVB as the main cause of SCD in these pa-
tients. Nonetheless, no signiﬁcant differences were
observed between NOP-LBBB and NOP-LBBB-PPM in
the risk of SCD. The ongoing MARE (Ambulatory
Electrocardiographic Monitoring for the Detection of
High-Degree Atrio-Ventricular Block in Patients With
New-onset PeRsistent LEft Bundle Branch Block After
Transcatheter Aortic Valve Implantation) study (38),
with continuous ECG recording (up to 3 years) in
patients with NOP-LBBB following TAVR should help
to clarify this issue.
The results of our study also highlight the impor-
tance of measuring the QRS duration in patients with
NOP-LBBB following TAVR. One of 10 patients with
TAVR who left the hospital with NOP-LBBB and a QRS
duration >160 ms died of SCD within the ﬁrst months
following the procedure (vs. <3% in patients with
NOP-LBBB and QRS #160 ms) (Central Illustration). A
higher rate of progression to advanced AVB may be
responsible for the high rate of SCD in such patients,
and the implantation of a preventive pacemaker
before hospital discharge may be justiﬁed while
awaiting results of further studies.
Considerable evidence supports the association
between left ventricular dysfunction and sudden
cardiac death (39). It is, therefore, not surprising that
patients with LVEF #40% were at higher risk of SCD
in this study (Central Illustration). Of note, patients
with both NOP-LBBB and an LVEF #40% exhibited
the highest rate of SCD (>12%) within the year
following TAVR, much higher than SCD rates in the
presence of only 1 of these factors (<5%). This may be
secondary to the occurrence of ventricular arrhyth-
mias, bradyarrhythmias, and/or even advanced HF
due to LBBB-related mechanical dyssynchrony. A
longer QRS duration was reported to be a predictor ofSCD in patients with HF (40), and impairment or lack
of improvement in LVEF in patients with NOP-LBBB
after TAVR (41,42) may also contribute to the
very high risk of SCD in patients with both
factors. Although the effectiveness of implantable
cardioverter-deﬁbrillator devices in patients age >80
years, particularly in those with associated comor-
bidities such as renal failure and chronic pulmonary
diseases (a large proportion of the TAVR popula-
tion), has not been conﬁrmed (39), future studies are
needed to evaluate the usefulness (and cost-
effectiveness) of implanting such devices in this
high-risk group of patients. Also, cardiac resynchro-
nization in patients with left ventricular dysfunc-
tion requiring ventricular pacing or implantable
cardioverter-deﬁbrillators has been associated with a
lower risk of death or rehospitalization for heart
failure (43). Whether biventricular pacing might be
associated with increased survival in patients with
reduced LVEF and NOP-LBBB or PPM after TAVR
should be further studied.
STUDY LIMITATIONS. Although the causes of death
in each center were deﬁned according to the VARC-2,
no event adjudication committee was available in
this study. ECG and echocardiographic ﬁndings were
interpreted in each center, with no ECG or echocar-
diography core laboratory evaluation. No contractile
reserve data was available in patients with low-ﬂow
low-gradient aortic stenosis. The occurrence of
CENTRAL ILLUSTRATION Predictors of Death From Heart Failure and Sudden Cardiac Death in Patients Undergoing TAVR
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Baseline comorbidities and procedural factors leading to an increased rate of death from heart failure and sudden cardiac death. Kaplan-Meier curves for potentially
modiﬁable or treatable factors are shown. TAVR ¼ transcatheter aortic valve replacement.
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446advanced AVB in patients with NOP-LBBB during
follow-up was not prospectively collected in all
participating centers and was not analyzed in order to
avoid major bias. Also, the number of patients in the
NOP-LBBB-PPM group was limited, and the potential
protective effect of PPM in patients with NOP-LBBB
should be interpreted with caution and needs
further investigation. Finally, although each center
collected data prospectively, data analysis was
retrospective.
CONCLUSIONS
Advanced HF and SCD accounted for approximately
two-thirds of cardiac deaths following TAVR,
which occurred most frequently during the ﬁrst 6
months after the procedure. Potentially modiﬁable
or treatable factors leading to increased risk of
mortality from HF and SCD were identiﬁed. Future
studies should evaluate whether speciﬁc therapeuticstrategies targeting these factors, such as alterna-
tives to the transapical approach in patients at
risk of advanced HF not suitable for transfemoral
access, further treatment of residual moderate or
severe AR (especially if acute increase vs. baseline),
pacemaker implantation in patients with NOP-LBBB
(particularly in the presence of QRS duration >160
ms), or cardiac deﬁbrillator implantation in patients
with left ventricular dysfunction, decrease these
patients’ risk of cardiac death. In the meantime, our
results allow identiﬁcation of the patients at the
highest risk of dying of HF or SCD within the ﬁrst
months following TAVR and should contribute to
improved clinical decision-making.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Josep Rodés-Cabau, Quebec Heart & Lung Institute,
Laval University, 2725 chemin Ste-Foy, G1V 4G5
Quebec City, Quebec, Canada. E-mail: josep.rodes@
criucpq.ulaval.ca.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Predic-
tors of cardiac death after TAVR include potentially
modiﬁable or treatable factors, such as a transapical
approach and moderate-severe residual AR, both associ-
ated with death from HF, and development of NOP-LBBB,
associated with SCD, particularly in those with QRS
duration >160 ms.
COMPETENCY IN PATIENT CARE: In managing
patients undergoing TAVR, physicians may consider
alternatives to a transapical approach in those patients
at risk of advanced HF (especially in those with severely
impaired ventricular function), treating residual AR
(especially in those with pulmonary hypertension or no/
trace AR at baseline), and implantation of a pacemaker or
deﬁbrillator in those with NOP-LBBB, QRS prolongation
>160 ms, and left ventricular dysfunction.
TRANSLATIONAL OUTLOOK: Randomized trials are
needed to deﬁne optimum management strategies for
patients with modiﬁable risk factors for development
of HF or cardiac death following TAVR.
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